KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Astrana Health (ASTH) EBITDA (2016 - 2025)

Astrana Health's EBITDA history spans 16 years, with the latest figure at $19.2 million for Q3 2025.

  • For Q3 2025, EBITDA fell 32.42% year-over-year to $19.2 million; the TTM value through Sep 2025 reached $60.8 million, down 28.21%, while the annual FY2024 figure was $89.4 million, 5.6% up from the prior year.
  • EBITDA for Q3 2025 was $19.2 million at Astrana Health, down from $20.3 million in the prior quarter.
  • Across five years, EBITDA topped out at $53.2 million in Q3 2021 and bottomed at -$115.2 million in Q2 2021.
  • The 5-year median for EBITDA is $21.8 million (2021), against an average of $15.8 million.
  • The largest annual shift saw EBITDA plummeted 992.8% in 2021 before it surged 459.65% in 2022.
  • A 5-year view of EBITDA shows it stood at $2.2 million in 2021, then soared by 459.65% to $12.6 million in 2022, then tumbled by 130.76% to -$3.9 million in 2023, then soared by 118.6% to $720000.0 in 2024, then skyrocketed by 2567.92% to $19.2 million in 2025.
  • Per Business Quant, the three most recent readings for ASTH's EBITDA are $19.2 million (Q3 2025), $20.3 million (Q2 2025), and $20.6 million (Q1 2025).